Невролупус
Article Sidebar
Main Article Content
Апстракт
Системски лупус еритематозус (СЛЕ) не е невообичаена состојба. Повеќето невролози се свесни дека тaa може да предизвика широк спектар на невролошки компликации, и СЛЕ речиси секогаш се појавува на листа на "диференцијална дијагноза“ во случаи на клиничка несигурност. Сепак, точната природа на манифестациите на СЛЕ во централниот и периферниот нервен систем е можеби помалку разбрана, и заблудите за феноменот и третманот се чести. Ќе бидат разгледани некои од главните примарни невролошки компликации на СЛЕ - 'невролупус' - земјќи во обзир дека второстепените проблеми во врска со други последици од СЛЕ (на пример, хипертензивна болест на ЦНС појава како резултат на бубрежен лупус) не се ниту помалку сериозни ниту пак може полесно да се лекуваат.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Референци
Jimйnez S, Cervera R, Font J, et al. The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2003;25:3–12. DOI: https://doi.org/10.1385/CRIAI:25:1:3
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. DOI: https://doi.org/10.1002/art.1780400928
Hanly JG, McCurdy G, Fougere L, et al. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. Rheumatol. 2004;31:2156–62.
Hanly JG, Fisk JD, McCurdy G, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol. 2005;32:1459–6.
Hanly JG, Su L, Farewell V, et al. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol. 2009;36:1449–59. DOI: https://doi.org/10.3899/jrheum.081133
Ainiala H, Loukkola J, Peltola J, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57:496–500. DOI: https://doi.org/10.1212/WNL.57.3.496
Scolding NJ, Joseph FG. The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathol Appl Neurobiol. 2002;28:173–89. DOI: https://doi.org/10.1046/j.1365-2990.2002.00406.x
Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore). 1968;47:337–69. DOI: https://doi.org/10.1097/00005792-196807000-00002
Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum. 1979;8:212–21. DOI: https://doi.org/10.1016/S0049-0172(79)80009-8
Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol. 1988;23:380–4. DOI: https://doi.org/10.1002/ana.410230411
Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992;19:732–41.
Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 2006;54:312–24. DOI: https://doi.org/10.1002/art.21539
Asherson RA, Cervera R, Merrill JT, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost. 2008;34:256–66. DOI: https://doi.org/10.1055/s-0028-1082269
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608. DOI: https://doi.org/10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F
Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain. 2004;127:1200–9. DOI: https://doi.org/10.1093/brain/awh146
Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus. 2006;15:191–7. DOI: https://doi.org/10.1191/0961203306lu2272rr
Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology. 2007;69:644–54. DOI: https://doi.org/10.1212/01.wnl.0000267320.48939.d0
Devreese K, Hoylaerts MF. Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. Eur J Haematol. 2009;83:1–16. DOI: https://doi.org/10.1111/j.1600-0609.2009.01243.x
Wong RC, Favaloro EJ. Clinical features, diagnosis, and management of the antiphospholipid syndrome. Semin Thromb Hemost. 2008;34:295–304. DOI: https://doi.org/10.1055/s-0028-1082275
Bayraktar UD, Erkan D, Bucciarelli S, et al; Catastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol. 2007;34:346–52.
Scolding NJ, ed. Systemic inflammatory diseases and the nervous system. In: Contemporary treatments in neurology. Oxford: Butterworth Heinemann, 2001:187–215.
Stojanovich L, Zandman-Goddard G, Pavlovich S, et al. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev. 2007;6:421–6. DOI: https://doi.org/10.1016/j.autrev.2007.02.007
Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford). 2008;47:1498–502. DOI: https://doi.org/10.1093/rheumatology/ken260
Denburg SD, Carbotte RM, Denburg JA. Cognition and mood in systemic lupus erythematosus. Evaluation and pathogenesis. Ann N Y Acad Sci. 1997;823:44–59. DOI: https://doi.org/10.1111/j.1749-6632.1997.tb48378.x
Kovacs B, Lafferty TL, Brent LH, et al. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000;59:120–4. DOI: https://doi.org/10.1136/ard.59.2.120
Espinosa G, Mendizábal A, Mínguez S, Ramo-Tello C, Capellades J, Olivé A, Cervera R. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum. 2010;39(4):246-56. DOI: https://doi.org/10.1016/j.semarthrit.2008.09.002
Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65:78–83. DOI: https://doi.org/10.1001/archneurol.2007.17
Fulford KW, Catterall RD, Delhanty JJ, et al. A collagen disorder of the nervous system presenting as multiple sclerosis. Brain. 1972;95:373–86. DOI: https://doi.org/10.1093/brain/95.2.373
Rosenbaum R. Neuromuscular complications of connective tissue diseases. Muscle Nerve. 2001;24:154–69. DOI: https://doi.org/10.1002/1097-4598(200102)24:2<154::AID-MUS20>3.0.CO;2-3
Vina ER, Fang AJ, Wallace DJ, et al. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome. Semin Arthritis Rheum. 2005;35:175–84. DOI: https://doi.org/10.1016/j.semarthrit.2005.08.008
Bhinder S, Majithia V, Harisdangkul V. Myasthenia gravis and systemic lupus erythematosus: truly associated or coincidental"”two case reports and review of the literature. Clin Rheumatol. 2006;25:555–6. DOI: https://doi.org/10.1007/s10067-005-0099-8
Cuchacovich R, Gedalia A. Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheum Dis Clin North Am. 2009;35:75–93. DOI: https://doi.org/10.1016/j.rdc.2009.03.003
Karassa FB, Ioannidis JP, Touloumi G, et al. Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM. 2000;93:169–74. DOI: https://doi.org/10.1093/qjmed/93.3.169
Creamer P, Kirwan J. Seronegative systemic lupus erythematosus. Br J Rheumatol. 1992;31:619–22. DOI: https://doi.org/10.1093/rheumatology/31.9.619
Craig WY, Ledue TB, Johnson AM, et al. The distribution of antinuclear antibody titers in "normal" children and adults. J Rheumatol. 1999;26:914–19.
Appenzeller S, Pike GB, Clarke AE. Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allergy Immunol. 2008;34:361–6. DOI: https://doi.org/10.1007/s12016-007-8060-z
Graham JW, Jan W. MRI and the brain in systemic lupus erythematosus. Lupus. 2003;12:891–6. DOI: https://doi.org/10.1191/0961203303lu498oa
Peterson PL, Axford JS, Isenberg D. Imaging in CNS lupus. Best Pract Res Clin Rheumatol. 2005;19:727–39. DOI: https://doi.org/10.1016/j.berh.2005.04.001
Castellino G, Govoni M, Giacuzzo S, et al. Optimizing clinical monitoring of central nervous system involvement in SLE. Autoimmun Rev. 2008;7:297–304. DOI: https://doi.org/10.1016/j.autrev.2007.11.022
Guttman M, Lang AE, Garnett ES, et al. Regional cerebral glucose metabolism in SLE chorea: further evidence that striatal hypometabolism is not a correlate of chorea. Mov Disord. 1987;2:201–10. DOI: https://doi.org/10.1002/mds.870020307
Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133–8. DOI: https://doi.org/10.1056/NEJM200312253492627
Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of highintensity warfarin vs. Conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848–53. DOI: https://doi.org/10.1111/j.1538-7836.2005.01340.x
Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295:1050–7. DOI: https://doi.org/10.1001/jama.295.9.1050
Trevisani VF, Castro AA, Neves Neto JF, et al. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev. 2006;19:CD002265. DOI: https://doi.org/10.1002/14651858.CD002265.pub2
Barile-Fabris L, Ariza-Andraca R, Olguнn-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620–5. DOI: https://doi.org/10.1136/ard.2004.025528